Chamberlain College of Nursing:NR 566 Week 5 final study guide Latest,100% CORRECT
5 vues 0 fois vendu
Cours
NR 566
Établissement
NR 566
Chamberlain College of Nursing:NR 566 Week 5 final study guide Latest
Chapter 18: Drugs Affecting the Hematopoietic System
• Know the pharmacodynamics, pharmacotherapeutics clinical use, drug interactions and adverse drug reactions for:
Anticoagulants
• Pharmacodynamics
• Oral an...
chamberlain college of nursingnr 566 week 5 final study guide latest
École, étude et sujet
NR 566
Tous les documents sur ce sujet (674)
Vendeur
S'abonner
paulhans
Avis reçus
Aperçu du contenu
Chamberlain College of Nursing:NR 566 Week 5 final study guide Latest
Chapter 18: Drugs Affecting the Hematopoietic System
• Know the pharmacodynamics, pharmacotherapeutics clinical use, drug interactions
and adverse drug reactions for:
Anticoagulants
• Pharmacodynamics
• Oral anticoagulants such as warfarin (Coumadin) inhibit the hepatic synthesis of several
clotting factors, including factor X.
• Heparin inhibits the activity of several activated clotting factors by accelerating
the activity of antithrombin III.
• LMWH enoxaparin (Lovenox) potentiates the activity of antithrombin III and inactivates
factors Xa and IIa (thrombin).
• Dabigatran (Pradaxa) is a direct thrombin inhibitor.
• Thrombin is required for the conversion of fibrinogen to fibrin in the
clotting cascade, thus dabigatran's inhibition of thrombin prevents
thrombi from forming.
• Fondaparinux (Arixtra) is a selective inhibitor of antithrombin III and a factor Xa inhibitor.
• Rivaroxaban (Xarelto) an anticoagulant, is a highly selective factor Xa inhibitor that inhibits
thrombin
formation and the development of thrombi.
• Apixaban (Eliquis) is a selective inhibitor of factor Xa.
• Aspirin antagonizes the cyclooxygenase pathway and interferes with platelet aggregation.
• NSAIDs have this same action.
• NSAIDs are not used as antiplatelet drugs, but this explains why
concurrent use with anticoagulants is contraindicated
• Ticlopidine (Ticlid) and clopidogrel (Plavix) reduce platelet aggregation by inhibiting the
ADP pathway of platelets.
• Unlike aspirin, they have no effect on prostaglandin metabolism.
• Ticagrelor (Brilinta) reversibly interacts with the platelet P2Y12 ADP-receptor to
prevent platelet activation.
• Vorapaxar (Zontivity) is a protease-activated receptor-1 (PAR-1) antagonist, inhibiting
thrombin-induced and thrombin receptor agonist peptide-induced platelet aggregation
• Pharmacotherapeutics:
• Precautions and Contraindications
• All anticoagulants are contraindicated for patients who are hypersensitive to the drug
, or actively bleeding or who have hemophilia, thrombocytopenia, severe HTN,
intracranial hemorrhage, infective endocarditis, active tuberculosis, or ulcerative
lesions of the GI tract.
• Heparins are contraindicated in advanced hepatic or renal disease.
• They may be used in patients who are actively bleeding to treat DIC
• Heparin is Pregnancy Category C: stillbirth, prematurity
• Some heparin preparations contain benzyl alcohol: known to cause “gasping
syndrome”:
• fatal toxicity in neonates
• Hyperkalemia may develop
, • Use for patient with DM or renal insufficiency requires care and frequent monitoring o
aPTT
• Has been associated with fatal medication errors r/t different strengths of preparation
• JCo: anticoagulant therapy is a National patient Safety Goal: plan in place at
each facility to reduce patient harm
• LMWHs are contraindicated for patients with allergies to pork, sulfites, or benzyl
alcohol; uncontrolled bleeding; and in patients who have antiplatelet antibodies
• Renal impairment: cautious use
• Body weight less than 50 kg associated with increased r/f bleeding:
• enoxaparin dose adjustment
• Cautious use: untreated HTN, retinopathy (HTN or DM caused), severe liver
disease, recent Hx of ulcer, or malignancy
• Not used for thromboprophylaxis in patients with mechanical heart values:
especially pregnant (r/f heart value thrombosis)
• Enoxaparin: Preg Cat B, tinzaparin: teratogenicity and fetal death, fondaparinux: Preg
• First line drug for women who require antithrombotic therapy during pregnancy:
LMWH
• Pharmacokinetics of LMWH is altered during pregnancy
• Warfarin
• Hepatic dysfunction potentiates response through impaired synthesis of coagulation
factors
• Use with caution: Hypermetabolic states produced by fever or
hyperthyroidism increase responsiveness to warfarin:
• r/t increased catabolism of vit K dependent coagulation factors
• Increased r/f bleeding in older adults
• Caution use based on balance between potential for decreased r/f
thromboembolism and the risk for bleeding especially in those with
dementia or severe cognitive impairment: Hx of three falls in the previous
year or recurrent injurious falls, uncontrolled HTN, or non-adherent or
unreliable
• Warfarin is Pregnancy Category X: Crosses placenta and can cause hemorrhagic
disorders in the fetus and serious birth defects
• Safe during lactation
• Rivaroxaban (Xarelto): Black-Box Warning: premature discontinuation of
anticoagulants including rivaroxaban may lead to thrombotic events.
• An increased risk of stroke is seen in patients with atrial fibrillation when
transitioning to warfarin
• Rivaroxaban is Pregnancy Category C and is not recommended for use in pregnant
women.
• Apixaban (Eliquis): Black Box warning premature discontinuation leading to thrombotic
events
• Although there are no well-controlled studies: Pregnancy Category B
• Hypersensitivity to aspirin and cross-sensitivity with NSAIDs may occur, contraindicating the
, drug
• Aspirin hypersensitivity is more prevalent in patients with asthma, nasal
polyps, or chronic urticaria.
• Reye syndrome has been associated with its use in children and teenagers who
have influenza or chickenpox.
• Reversible hepatotoxicity has occurred
• Use with caution in liver damage, preexisting hypoprothrombinemia, or vit K deficienc
• Preg Cat C and Cat D in third trimester
• Avoid during lactation
• Clopidogrel and ticlopidine: severe hepatic disease (r/f bleeding d/o), do not use in these
patients
• Not recommended for patients with GI d/o
• Preg Category B
• Ticlopidine: clearance increased with age, older adults increased sensitivity to
this drug (closely monitor or ADRs)
• Older adults: increased levels of clopidogrel: no dosage adjustments
• In older adults clopidogrel is a safer drug
Les avantages d'acheter des résumés chez Stuvia:
Qualité garantie par les avis des clients
Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.
L’achat facile et rapide
Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.
Focus sur l’essentiel
Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.
Foire aux questions
Qu'est-ce que j'obtiens en achetant ce document ?
Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.
Garantie de remboursement : comment ça marche ?
Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.
Auprès de qui est-ce que j'achète ce résumé ?
Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur paulhans. Stuvia facilite les paiements au vendeur.
Est-ce que j'aurai un abonnement?
Non, vous n'achetez ce résumé que pour €15,94. Vous n'êtes lié à rien après votre achat.
